Inventor · disambiguated record
Gundo Diedrich
Also filed as: DIEDRICH GUNDO
17 granted patents·13 pending applications·109 citations·filing 2007–2024
93Inventor score
Files withMACROGENICS INC9LABORATORY CORP AMERICA HOLDINGS5MEDIMMUNE LTD5LAB CORP AMERICA HOLDINGS4DIADEXUS INC3
Top patents by PatentIndex Score
30 records- 0195US8349574B2Methods of determining patient response by measurement of Her-3LAB CORP AMERICA HOLDINGS·Filed 2010·Granted Jan 8, 2013·42 cites·51 claims
- 0294US9938356B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2015·Granted Apr 10, 2018·26 cites·9 claims
- 0391US10287362B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2018·Granted May 14, 2019·10 cites·15 claims
- 0489US11459394B2Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2018·Granted Oct 4, 2022·4 cites·8 claims
- 0588US9766242B2Methods of determining patient response by measurement of HER-3 and P95LABORATORY CORP AMERICA HOLDINGS·Filed 2015·Granted Sep 19, 2017·3 cites·14 claims
- 0687US11942149B2Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2022·Granted Mar 26, 2024·1 cites·14 claims
- 0785US9110066B2HER-3 antibodies and methods of useLAB CORP AMERICA HOLDINGS·Filed 2012·Granted Aug 18, 2015·4 cites·34 claims
- 0883US11242402B2ADAM9-binding molecules, and methods of use thereofMACROGENICS INC·Filed 2017·Granted Feb 8, 2022·2 cites·38 claims
- 0983US8906369B2Ovr110 antibody compositions and methods of useDIADEXUS INC·Filed 2013·Granted Dec 9, 2014·6 cites·4 claims
- 1082US8444971B2OVR110 antibody compositions and methods of usePAPKOFF JACKIE·Filed 2007·Granted May 21, 2013·7 cites·17 claims
- 1181US10556968B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Feb 11, 2020·2 cites·8 claims
- 1280US2025115676A1ADAM9-Binding Molecules, and Methods of Use ThereofMACROGENICS INC·Filed 2024·Application pending·0 cites
- 1379US2023340152A1Binding molecules specific for cd73 and uses thereofMEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 1473US8354508B2PRO115 antibody compositions and methods of useDIADEXUS INC·Filed 2007·Granted Jan 15, 2013·2 cites·18 claims
- 1572US11525012B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Dec 13, 2022·0 cites·6 claims
- 1671US2023062274A1Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer PatientsLABORATORY CORP AMERICA HOLDINGS·Filed 2022·Application pending·0 cites
- 1771US2024233818A1Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2024·Application pending·0 cites
- 1870US2022324995A1ADAM9-Binding Molecules, and Methods of Use ThereofMACROGENICS INC·Filed 2021·Application pending·0 cites
- 1965US10775382B2Methods of determining patient response by measurement of HER-3LABORATORY CORP AMERICA HOLDINGS·Filed 2017·Granted Sep 15, 2020·0 cites·22 claims
- 2062US11401344B2Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patientsLABORATORY CORP AMERICA HOLDINGS·Filed 2018·Granted Aug 2, 2022·0 cites·11 claims
- 2160US2014370523A1Methods of Determining Patient Response by Measurement of HER-2 ExpressionLAB CORP AMERICA HOLDINGS·Filed 2014·Application pending·0 cites
- 2258US2017082626A1Methods of Determining Patient Response by Measurement of HER-2 ExpressionLABORATORY CORP AMERICA HOLDINGS·Filed 2016·Application pending·0 cites
- 2357US2015175701A1Ovr110 antibody compositions and methods of useDIADEXUS INC·Filed 2014·Application pending·0 cites
- 2454US12435155B2CD137 binding molecules and uses thereofMACROGENICS INC·Filed 2021·Granted Oct 7, 2025·0 cites·17 claims
- 2550US2010233732A1Methods of Determining Patient Response By Measurement of HER-2 ExpressionLAB CORP AMERICA HOLDINGS·Filed 2010·Application pending·0 cites
- 2650US2021275685A1Immunoconjugates targeting adam9 and methods of use thereofIMMUNOGEN INC·Filed 2019·Application pending·0 cites
- 2748US2010074893A1ECM-Complex Antibody Compositions and Methods of UseBISTRUP ANNETTE·Filed 2009·Application pending·0 cites
- 2847US2021246194A1Optimized gp41-Binding Molecules and Uses ThereofMACROGENICS INC·Filed 2019·Application pending·0 cites
- 2946US11795226B2Bispecific CD16-binding molecules and their use in the treatment of diseaseMACROGENICS INC·Filed 2018·Granted Oct 24, 2023·0 cites·20 claims
- 3044US2021388102A1Immunoconjugates targeting adam9 and methods of use thereofIMMUNOGEN INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gundo Diedrich files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →